REWARDS TLX: REGISTRY EXPERIENCE AT WASHINGTON HOSPITAL CENTER: TAXUS LIBERTÉ VS XIENCE V

i2 Poster Contributions
Ernest N. Morial Convention Center, Hall F
Monday, April 04, 2011, 9:30 a.m.-10:45 a.m.

Session Title: PCI - DES III
Abstract Category: 16. PCI - DES (clinical/outcomes)
Session-Poster Board Number: 2508-508

Authors: Ron Waksman, Magdi Ghali, Randy Goodroe, Thomas Ryan, Mark Turco, Michael Ring, Thomas McGarry, David Dobies, Nicolas Shammas, Daniel Steinberg, Stacy Swymelar, Rebecca Torguson, Cardiovascular Research Institute, Washington, DC

Background: The emergence of the everolimus-eluting stent has generated large amounts of clinical trial data comparing this option to paclitaxel-eluting stents. This study aimed to show the noninferiority of the TAXUS Liberte (TL) stent to the XIENCE V (XV) stent at 1-year follow-up.

Methods: The study included a US all-comers population treated with either TL or XV stents, at 10 sites. Patients receiving TL (n=595) and XV (n=600) were compared at 1-year post-implantation. The primary endpoint is major adverse cardiac events (MACE), a composite of all-cause death, Q-wave myocardial infarction, and target vessel revascularization. Secondary endpoints include stent thrombosis, target lesion revascularization and cardiac death. There is also a subanalysis comparing diabetics and nondiabetics.

Results: Baseline demographics were similar between groups except the TL group was older while the XV group had more hypertension and family history of CAD. In-hospital outcomes were similar between groups. At 1 year, MACE was significantly higher in the TL group (11.6% vs. 8.0%, p=0.037). After adjusting for baseline differences there was a 66% decrease in MACE at 1 year for patients receiving XV vs TL (1.66 [1.51-2.11], p=0.008). (Figure) In the diabetic group this finding was not consistent (9.0% vs 13.6% XV and TL, respectively, p=0.143).

Conclusions: In regards to the primary endpoints, the XV stent was found to be superior to TL, mainly driven by a TLR rate in the TL group with no difference in death, MI or ST.

Figure: Adjusted Cox Regression at 1 year for Xience V vs Taxus Liberte